Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2020—Qiagen announced the CE marking and launch of its Therascreen PIK3CA RGQ PCR Kit in Europe as an aid in identifying breast cancer patients with a PIK3CA mutation. The Therascreen PIK3CA test was approved in 2019 by the FDA and launched in the U.S. as a companion diagnostic test for Piqray (alpelisib).
March 2020—Beckman Coulter’s Access PCT assay has received FDA 510(k) clearance and is available for sale in the United States. The assay enables health care providers to integrate procalcitonin testing analysis into their routine sepsis workups on core laboratory analyzers, as a primary or reflex test programmed through Beckman Coulter’s Remisol Advance middleware. Test results are available in less than 20 minutes.
March 2020—Thermo Fisher Scientific and NanoPin Technologies have entered into a collaborative relationship to advance blood-based infectious disease detection technology through the development of highly sensitive liquid chromatography-mass spectrometry–based workflows.
March 2020—Agilent Technologies introduced the SureSelect XT HS2 DNA Kit, designed to address key challenges that laboratories encounter when preparing DNA sequencing libraries for their research.
March 2020—Biodesix and Streck announced a regulatory cooperation agreement that will further enable the companies to pursue FDA approval for diagnostic testing services and specimen collection products.
March 2020—Hamilton Storage introduced the LabElite DeFroster for removing frost on tube racks. The unit automatically draws a single rack into one end where mechanical brushes and a liquid solvent remove frost in less than 10 seconds, then the rack is sent out the opposite end. The platform will not warm samples more than 15°C, ensuring sample integrity, can operate in a cold room environment ranging from +10°C to +30°C, and is mobile, allowing users to perform work while using battery power. The defroster is compatible with tube types up to 90 mm high.
February 2020—Olympus and Ultivue, a developer of tissue biomarker identification and quantification assays for translational research, have entered into a comarketing agreement. The partnership will provide a solution for fluorescent multiplexing by combining the Olympus Slideview VS200 automated slide scanner with Ultivue’s proprietary InSituPlex DNA barcoding and staining technology to provide quantitative colocalization analysis in fluorescent whole slide images.
February 2020—SeraCare Life Sciences launched genomic DNA and formalin-fixed, paraffin-embedded reference materials for tumor mutational burden measurement by next-generation sequencing assays. SeraCare collaborated with Friends of Cancer Research and International Quality Network for Pathology in the development and evaluation of a range of gDNA and FFPE-based TMB reference materials across different targeted NGS panels, sequencing platforms, and bioinformatics analysis pipelines.
February 2020—DiaSorin Molecular has received FDA clearance for its Simplexa VZV Swab Direct assay. The CLIA moderate-complexity assay is designed for use on the Liaison MDX instrument to detect varicella-zoster virus DNA from cutaneous and mucocutaneous swab specimens. The assay complements the company’s Simplexa VZV Direct kit, which is for use with cerebrospinal fluid samples.
February 2020—Applied BioCode has received FDA 510(k) clearance for its BioCode Respiratory Pathogen Panel for use on the company’s BioCode MDx-3000 system. The panel tests nasopharyngeal swabs for common viruses and bacteria, including influenza A and subtypes H1, H1N1 2009pdm, and H3; influenza B; respiratory syncytial virus A/B; parainfluenza virus types 1–4; human metapneumovirus A/B; adenovirus; rhinovirus/enterovirus; coronavirus (229E, NL63, OC43, and HKU1); Mycoplasma pneumoniae; Chlamydia pneumoniae; and Bordetella pertussis.
